Therapeutically, a number of NAFLD pharmacotherapies appear to lower TNF-α, thus their effects may be mediated, at least in part, through suppressing TNF-α, which, however, remains to be elucidated. This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.